JNJ

225.75

-0.8%↓

ABT

92.6

+1.52%↑

MDT

83.1

-0.34%↓

115.96

+0.48%↑

VEEV

161.87

+0.64%↑

JNJ

225.75

-0.8%↓

ABT

92.6

+1.52%↑

MDT

83.1

-0.34%↓

115.96

+0.48%↑

VEEV

161.87

+0.64%↑

JNJ

225.75

-0.8%↓

ABT

92.6

+1.52%↑

MDT

83.1

-0.34%↓

115.96

+0.48%↑

VEEV

161.87

+0.64%↑

JNJ

225.75

-0.8%↓

ABT

92.6

+1.52%↑

MDT

83.1

-0.34%↓

115.96

+0.48%↑

VEEV

161.87

+0.64%↑

JNJ

225.75

-0.8%↓

ABT

92.6

+1.52%↑

MDT

83.1

-0.34%↓

115.96

+0.48%↑

VEEV

161.87

+0.64%↑

Home・Akcijų sąrašas・Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

29.83 8.87

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

27.4

Max

32.56

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-85K 53M
Pardavimai	4.2M 153M
P/E Sektoriaus vid.	15.518 60.328
Pelnas, tenkantis vienai akcijai	0.68
Pelno marža	34.53
Darbuotojai	182
EBITDA	612K 81M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+26.05% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	241M 3.2B
Ankstesnė atidarymo kaina	20.96
Ankstesnė uždarymo kaina	29.83

Naujienos nuotaikos

By Acuity

28%

72%

62 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

N/A / 24.28 Palaikymas ir pasipriešinimas

Catalyst Pharmaceuticals Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-26 21:14; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Major Central Bank Meetings Due as Middle East Conflict Continues

2026-04-26 21:14; UTC

Svarbiausios naujienos

Week Ahead for FX, Bonds: Major Central Bank -2-

2026-04-24 19:19; UTC

Įsigijimai, susijungimai, perėmimai

Intertek Group Rejects EQT's Revised Offer

2026-04-26 23:48; UTC

Rinkos pokalbiai

Nikkei May Rise After U.S. Tech Gains -- Market Talk

2026-04-26 23:44; UTC

Uždarbis

Sinopharm 1Q Net CNY1.41B Vs. Net CNY1.46B >1099.HK

2026-04-26 23:44; UTC

Uždarbis

Sinopharm 1Q Rev CNY140.77B Vs. CNY141.66B >1099.HK

2026-04-26 23:36; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Falls Amid Dollar's Strength -- Market Talk

2026-04-26 23:33; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Rises Amid Ongoing Middle East Tensions -- Market Talk

2026-04-26 05:12; UTC

Uždarbis

Citic Securities: Results Also Aided by Higher Income from Brokerage, Income Banking Business >6030.HK

2026-04-26 05:12; UTC

Uždarbis

Citic Securities: Increase in Net Interest Income Supported Results >6030.HK

2026-04-26 05:12; UTC

Uždarbis

Citic Securities 1Q Rev CNY23.16B Vs. CNY16.43B >6030.HK

2026-04-26 05:12; UTC

Uždarbis

Citic Securities 1Q Net CNY10.22B Vs. Net CNY6.61B >6030.HK

2026-04-24 23:37; UTC

Įsigijimai, susijungimai, perėmimai

Scoring the Cook Era -- Barrons.com

2026-04-24 20:51; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 20:50; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Financial Services Roundup: Market Talk

2026-04-24 20:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-04-24 20:39; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 31% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 20:09; UTC

Uždarbis

Tesla Stock Rises After Upgrade But Heads for Weekly Loss. Why AI Is Key. -- Barrons.com

2026-04-24 19:48; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Oil Posts Weekly Gains on Continued Hormuz Closure -- Market Talk

2026-04-24 19:25; UTC

Įsigijimai, susijungimai, perėmimai

Organon Stock Surges 30% on Sweetened $13 Billion Takeover Offer From Sun Pharma -- Barrons.com

2026-04-24 19:25; UTC

Įsigijimai, susijungimai, perėmimai

QXO Continues to Tumble Following TopBuild Deal -- Barrons.com

2026-04-24 19:22; UTC

Uždarbis

Dell AI Infrastructure Deal Shows That Hyperscalers Aren't the Only Players. Plus, Adobe and 4 More Stocks. -- Barrons.com

2026-04-24 19:06; UTC

Uždarbis

Earnings Season Was Supposed to Drive the Stock Market. Why It Hasn't. -- Barrons.com

2026-04-24 19:05; UTC

Rinkos pokalbiai

U.S. Natural Gas Falls As Market Frets Over Storage -- Market Talk

2026-04-24 18:30; UTC

Įsigijimai, susijungimai, perėmimai

Intertek: EQT's GBP54/Shr Offer 'Fundamentally Undervalues Intertek and Its Future Prospects'

2026-04-24 18:28; UTC

Įsigijimai, susijungimai, perėmimai

Intertek Rejects Revised EQT Offer

2026-04-24 18:12; UTC

Rinkos pokalbiai

Precious Metals Rise, But Remain Negative for the Week -- Market Talk

2026-04-24 18:06; UTC

Rinkos pokalbiai

Oil Futures Extend Losses on Plans for U.S.-Iran Talks -- Market Talk

2026-04-24 17:42; UTC

Uždarbis

Even Nvidia Stock Is Getting an Intel Boost. It's on Pace for a Record High. -- Barrons.com

2026-04-24 17:28; UTC

Uždarbis

Palantir Stock Is Down 20% in 2026. Why This Analyst Says It's a Buy. -- Barrons.com

Akcijų palyginimas

Kainos pokytis

Catalyst Pharmaceuticals Inc Prognozė

Kainos tikslas

By TipRanks

26.05% į viršų

12 mėnesių prognozė

Vidutinis 34.5 USD 26.05%

Aukščiausias 35 USD

Žemiausias 33 USD

Remiantis 5 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Catalyst Pharmaceuticals Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

5 ratings

Pirkti

Laikyti

Parduoti

Remiantis 5 analitikų, pateikusių Catalyst Pharmaceuticals Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

N/A / 24.28Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bullish.

Rinkos nuotaikos

By Acuity

62 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Catalyst Pharmaceuticals Inc

Catalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis and spinal muscular atrophy type. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was founded in 2002 and is based in Coral Gables, Florida.